Trevor Martin (Mammoth)

Eye­ing in-vi­vo edit­ing, Mam­moth li­cens­es Jen­nifer Doud­na’s new CRISPR en­zyme

Last month, Jen­nifer Doud­na re­vealed in Sci­ence a new, “hy­per-com­pact” CRISPR en­zyme that was half the size of tra­di­tion­al CRISPR en­zymes and could, she sus­pect­ed, of­fer a new, more ver­sa­tile tool for gene edit­ing.

Now, the Uni­ver­si­ty of Cal­i­for­nia-Berke­ley has li­censed that en­zyme, known as Casφ, ex­clu­sive­ly to a biotech start­up she and two for­mer stu­dents set up three years ago: Mam­moth Bio­sciences. It’s the sec­ond new CRISPR pro­tein Mam­moth has li­censed from Doud­na’s lab, af­ter they li­censed Cas14 in 2019.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.